INS and metabolic dysfunction-associated steatotic liver disease: Proposed pathophysiologic mechanisms that may lead to MASLD improvement under SGLT-2i treatment include reduced glucose and insulin levels, which in turn, lead to reduced de novo endohepatic lipid synthesis and increased glucagon secretion from alpha pancreatic cells that also express SGLT-2.